Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Publication Date: February 28, 2024

Key Points

Key Points

The treatment of advanced stage IV non-small-cell lung cancer (NSCLC) has evolved dramatically in the past decade.
This clinical practice guideline update addresses two overarching clinical questions:
  1. What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
  2. What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?

Treatment

Treatment

...ecommendations with multiple treatment...


...al Question 1: What are the most effective fir...

...us Cell Carcinoma (Non-SCC)...

...ients with programmed death-ligand 1...

...ients with a programmed death-ligand 1 or p...

...patients with a programmed death-ligand...

...tients with a programmed death-liga...

...For patients with a programmed death-lig...

...nts with a programmed death-ligand 1...

...ts with a programmed death-ligand 1 or programme...

...PD-L1 expression TPS, 1–49%:...

...atients with PD-L1 expression TPS, 1–49...

...For patients with PD-L1 expression TPS, 1...

...patients with PD-L1 expression TPS, 1–49%, clin...

...ents with PD-L1 expression TPS, 1–49%, cli...

...patients with PD-L1 expression TPS, 1–49...

...For patients who are ineligible for or d...

...th unknown or negative PD-L1 expression, T...

...s with unknown or negative PD-L1 expressio...

...For patients with unknown or negative PD-L1 e...

...ents with unknown or negative PD-L1 expressio...

...tients with unknown or negative PD-L1 ex...

...ents with unknown or negative PD-L1 expression...

...ous Cell Carcinoma (S...

...tients with PD-L1 expression, TPS ≥50%...

...s with PD-L1 expression, TPS ≥50%,, clinici...

...patients with PD-L1 expression, TPS ≥...

.... For patients with PD-L1 expression,...

...atients with PD-L1 expression, TPS ...

...s with PD-L1 expression, TPS ≥50...

...PD-L1 expression TPS, 1–49%:...

....6. For patients with PD-L1 express...

...7. For patients with PD-L1 expression TPS, 1...

...ents with PD-L1 expression TPS, 1–49%...

...r patients with PD-L1 expression TPS, 1...

4.0. For patients with PD-L1 expression TPS,...

...unknown or negative PD-L1 expression,...

...patients with unknown or negative PD-L1 expressio...

...s with unknown or negative PD-L1 expr...

...For patients with unknown or negative PD-L1...

...For patients with unknown or negative PD-...

...s with Unspecified Histolo...

...For patients with unknown or negative PD-L...

...For patients with unknown or negative PD-L1 exp...

...ients with unknown or negative PD-L1 e...

...evacizumab should be avoided for patients w...

...tients with contraindications to bevacizumab...

...tients with Unspecified Histolo...

...vacizumab should be avoided for patients with squ...

...nance bevacizumab given with pemet...


...al Question 2: What are the most effective...

...previously treated with immune checkpoint the...

...or patients previously treated with immune chec...

...reviously treated with chemotherap...

...nts previously treated with chemotherapy and imm...

...n patients previously treated with chemotherapy...


.... Second-Line and Subsequent Treatment Optio...


.... First-Line Treatment Options for Patients...


.... First-Line Treatment Options for Patient...